Nimotuzumab-Induced Hypertension: A Maiden Case Report

Balaji, O and Amita, D and Patil, Navin (2017) Nimotuzumab-Induced Hypertension: A Maiden Case Report. Asian Journal of Pharmaceutical and Clinical Research, 10 (4). pp. 8-9. ISSN 0974-2441

[img] PDF
2353 DisplayPdf.pdf - Published Version
Restricted to Registered users only

Download (321kB) | Request a copy


Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70- ear-old man treated for vocal cord carcinoma.

Item Type: Article
Uncontrolled Keywords: Nimotuzumab; Hypertension; Epidermal growth factor receptor; Adverse effects
Subjects: Medicine > KMC Manipal > Pharmacology
Depositing User: KMC Library
Date Deposited: 08 Apr 2017 09:50
Last Modified: 08 Apr 2017 09:50

Actions (login required)

View Item View Item